Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Active, not recruiting · NCT06717464 · Registry updated 2024-12-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract disorder, carcinoma, cholangiocarcinoma, distal cholangiocarcinoma, epithelial neoplasm, gallbladder disorder, gallbladder neoplasm, hilar cholangiocarcinoma, neoplasm | Active, not recruiting | Phase 2 | 2024-12-05 | NCT06717464 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital | Tianjin | China | 66 |